1. Search Result
Search Result
Results for "

GAS6

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

3

Inhibitory Antibodies

1

Natural
Products

9

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2995
    Poricoic acid A
    1 Publications Verification

    Poricoic acid A(F)

    NF-κB Keap1-Nrf2 AMPK TGF-beta/Smad Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin .
    Poricoic acid A
  • HY-119039
    RU-301
    1 Publications Verification

    TAM Receptor Inflammation/Immunology Cancer
    RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .
    RU-301
  • HY-P99463
    Batiraxcept
    2 Publications Verification

    AVB-500; AVB-S6-500

    TAM Receptor PI3K Akt p38 MAPK Cancer
    Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
    Batiraxcept
  • HY-124066

    TAM Receptor Cancer
    RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC50in cell assays, and suppresses lung cancer tumor growth .
    RU-302
  • HY-P99161

    BGB149

    TAM Receptor Cancer
    Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas .
    Tilvestamab
  • HY-RS16715

    Small Interfering RNA (siRNA) Others

    Gas6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gas6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gas6 Mouse Pre-designed siRNA Set A
    Gas6 Mouse Pre-designed siRNA Set A
  • HY-177332

    TAM Receptor SARS-CoV Akt Infection Cancer
    SLC-391 is an orally active AXL kinase inhibitor with an IC50 of 9.6 nM against AXL kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer .
    SLC-391
  • HY-RS23150

    Small Interfering RNA (siRNA) Others

    Gas6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gas6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gas6 Rat Pre-designed siRNA Set A
    Gas6 Rat Pre-designed siRNA Set A
  • HY-RS05285

    Small Interfering RNA (siRNA) Others

    GAS6 Human Pre-designed siRNA Set A contains three designed siRNAs for GAS6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GAS6 Human Pre-designed siRNA Set A
    GAS6 Human Pre-designed siRNA Set A
  • HY-149092

    TAM Receptor Cancer
    Anticancer agent 109 (compound 6-15) is an inhibitor of the Gas6-Axl axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models .
    Anticancer agent 109
  • HY-P992231

    TAM Receptor Inflammation/Immunology
    Anti-GAS6 Antibody (KM5321) is a humanized anti-GAS6 monoclonal antibody. Its isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Anti-GAS6 Antibody (KM5321)
  • HY-152075

    TAM Receptor Cancer
    AXL-IN-14 is a potent and orally active AXL inhibitor with an IC50 value of 0.8 nM. AXL-IN-14 inhibits Gas6/AXL-mediated cell migration and invasion. AXL-IN-14 decreases the expression of p-AXL and p-AKT proteins. AXL-IN-14 shows anti-tumor activity .
    AXL-IN-14
  • HY-179535

    TAM Receptor Discoidin Domain Receptor TGF-β Receptor Hedgehog Cancer
    Axl-IN-21 is an orally active and selective AXL inhibitor (Kd = 2.7 nM, IC50 = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with Kd = 1.4 nM, DDR1 with IC50 = 22.2 nM, HIPK4 with Kd = 11.0 nM and LOK with Kd =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced AXL/STAT3/ABCG1 signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer [1] [2] .
    Axl-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: